Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-03-03 4:18 pm Purchase | 13G | Quoin Pharmaceuticals, Ltd. QNRX | Lind Global Fund II LP | 990,000 9.9% | 990,000 (New Position) | View |
| 2023-02-14 2:40 pm Purchase | 13G | Quoin Pharmaceuticals, Ltd. QNRX | GOLDMAN SACHS GROUP INC GS | 50 0% | 50 (New Position) | View |
| 2023-02-14 11:25 am Sale | 13G | Quoin Pharmaceuticals, Ltd. QNRX | CVI Investments Inc. | 1,272,737,541 4.9% | -227,262,459 (-15.15%) | View |
| 2022-08-12 10:01 am Purchase | 13G | Quoin Pharmaceuticals, Ltd. QNRX | CVI Investments Inc. | 1,500,000,000 8.2% | 1,500,000,000 (New Position) | View |
| 2022-03-10 3:26 pm Purchase | 13G | Quoin Pharmaceuticals, Ltd. QNRX | GOLDMAN SACHS GROUP INC GS | 1,450,549 17.4% | 679,650 (+88.16%) | View |
| 2022-02-14 3:06 pm Purchase | 13G | Quoin Pharmaceuticals, Ltd. QNRX | Altium Capital Management LP | 4,276,252 4.99% | 3,037,823 (+245.30%) | View |
| 2022-02-10 4:32 pm Purchase | 13G | Quoin Pharmaceuticals, Ltd. QNRX | GOLDMAN SACHS GROUP INC GS | 770,899 9.2% | 770,899 (New Position) | View |
| 2021-11-12 2:20 pm Purchase | 13G | Quoin Pharmaceuticals, Ltd. QNRX | Altium Capital Management LP | 1,238,429 9.99% | 1,238,429 (New Position) | View |
| 2021-02-16 09:42 am Sale | 13G | Cellect Biotechnology Ltd. APOP | CVI Investments Inc. | 0 0% | -30,500,000 (Position Closed) | View |
| 2021-01-13 09:03 am Sale | 13G | Cellect Biotechnology Ltd. APOP | Empery Asset Management LP | 185,200 0.05% | -32,114,800 (-99.43%) | View |
| 2020-04-22 3:14 pm Sale | 13D | Cellect Biotechnology Ltd. APOP | Yarkoni Shai | 21,197,983 6.2% | -15,202,859 (-41.77%) | View |
| 2020-02-14 4:23 pm Sale | 13G | Cellect Biotechnology Ltd. APOP | Anson Funds Management LP | 233,330 0.1% | -16,366,686 (-98.59%) | View |
| 2020-01-17 08:58 am Purchase | 13G | Cellect Biotechnology Ltd. APOP | CVI Investments Inc. | 30,500,000 9.4% | 30,500,000 (New Position) | View |
| 2020-01-10 1:51 pm Purchase | 13G | Cellect Biotechnology Ltd. APOP | Empery Asset Management LP | 32,300,000 9.97% | 32,300,000 (New Position) | View |
| 2020-01-03 12:52 pm Sale | 13G | Cellect Biotechnology Ltd. APOP | SABBY MANAGEMENT LLC | 111,820 11% | -728,313 (-86.69%) | View |
| 2019-02-20 4:40 pm Purchase | 13D | Cellect Biotechnology Ltd. APOP | Yarkoni Shai | 36,400,842 16.7% | 3,531,102 (+10.74%) | View |
| 2019-02-19 5:19 pm Purchase | 13G | Cellect Biotechnology Ltd. APOP | Anson Funds Management LP | 16,600,016 7.7% | 16,600,016 (New Position) | View |
| 2019-02-14 11:32 am Sale | 13G | Cellect Biotechnology Ltd. APOP | Michael Ilan Management & Investment Ltd. | 14,489,100 11.1% | -2,473,360 (-14.58%) | View |
| 2019-02-12 3:02 pm Sale | 13G | Cellect Biotechnology Ltd. APOP | SABBY MANAGEMENT LLC | 840,133 11% | -3,960,507 (-82.50%) | View |
| 2019-01-03 3:21 pm Sale | 13G | Cellect Biotechnology Ltd. APOP | SABBY MANAGEMENT LLC | 4,800,640 11% | -2,472,080 (-33.99%) | View |